ClinicalTrials.gov
ClinicalTrials.gov Menu

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02704767
Recruitment Status : Not yet recruiting
First Posted : March 10, 2016
Last Update Posted : March 10, 2016
Sponsor:
Information provided by (Responsible Party):
Li Rong-qing, The First Affiliated Hospital of Kunming Medical College

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Not yet recruiting
  Estimated Primary Completion Date : June 2019
  Estimated Study Completion Date : December 2019
Publications:
Qin S. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2014; 32(Suppl):Abst 4003.
Zhang L, Shi M, Huang C, et al. A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. J Clin Oncol. 2012;30(Suppl):Abst 7548.